Biomerica, Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the Helicobacter pylori bacteria. The company has strategic partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs for launching the inFoods platform in Canada. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Real-world clinical experience with the novel IBS-specific guided diagnostic therapy to be presented at the world’s largest GI medical conference, May 2–5, 2026, in ChicagoIRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global biomedical technology company focused on innovative diagnostic-guided therapies, today announced that an abstract evaluating the real-world clinical effectiveness of its inFoods® IBS diagnostic-guided therapy has been accepted for poste
IRVINE - Biomerica, Inc. , a global provider of advanced diagnostic solutions, announced that the Medicare Administrative Contractor responsible for processing inFoods IBS claims has confirmed to the...
Company and Laboratory Partner Believe Properly Documented Claims Are Positioned for Payment Under Existing $300 CMS Reimbursement RateThe Medicare Administrative Contractor (MAC) responsible for processing inFoods® IBS claims has confirmed to Biomerica’s certified laboratory partner that the test will be reviewed on an individual, claim-by-claim basis under Medicare’s standard claims approval process.The Company’s laboratory partner believes that properly documented claims — with appropriate di
Biomerica, Inc. (NASDAQ:BMRA), a global provider of advanced diagnostic solutions, today announced that the Medicare Administrative Contractor (MAC) responsible for processing inFoods® IBS claims has confirmed to
IRVINE - Biomerica, Inc. , a global biomedical technology company focused on innovative diagnostic-guided therapies, announced the commercial launch of its inFoods platform in Canada through two...
Biomerica, Inc. announced the commercial launch of its inFoods platform in Canada through two strategic partnerships: Phoenix Airmid Biomedical, which will serve as the exclusive Canadian distribution...
Biomerica, Inc. announced the commercial launch of its inFoods platform in Canada through two strategic partnerships: Phoenix Airmid Biomedical, which will serve as the exclusive Canadian distribution...
— Represents Biomerica’s First Commercial Entry into the Canadian Market for its Precision, Diagnostic-Guided Therapy — Canada Has One of the Highest IBS Prevalence Rates in the World — an Estimated 18% vs. 11% Globally — Up to Five Million Canadians May Have IBS, Representing a Significant and Underserved Market Opportunity IRVINE, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (“Biomerica” or the “Company”), a global biomedical technology company focused on innovativ
Biomerica (NASDAQ:BMRA) reported quarterly losses of $(0.44) per share. This is a 8.33 percent increase over losses of $(0.48) per share from the same period last year. The company reported $987.000 thousand in sales
IRVINE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (“Biomerica” or the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the third quarter of fiscal 2026 ended February 28, 2026. Key Highlights: 1. inFoods® IBS Real-World Data: Nearly 60% of Irritable Bowel Syndrome (“IBS”) Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with inFoods® IBS During the t
First Commercial Order by Large Lab Chain: Biomerica has received its first commercial order for Hp Detect™, from one of the largest clinical laboratory chains operating across Europe.Strategic Account: This new
Registration marks the Company’s entry into the UK market, where H. pylori affects an estimated 45% of the population across Europe’s five largest countriesUK Market Entry: MHRA registration authorizes hp+detect™ for commercial sale in Great BritainActive Commercialization: Biomerica is in active discussions with UK partners to access the diagnostic laboratory market and expects to provide further updates as agreements are finalized.Disease Burden: The WHO designates H. pylori as a Class 1 carci
Physician Interview Now AvailableKey Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent with the Company’s peer-reviewed randomized controlled trial.CMS Payment Rate: $300 national Medicare payment rate established, effective January 1, 2026.Physician Perspective: New interview with Gastroenterologist Dr. Dak Patel about inFoods IBS in clinical use now availab
Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent with the Company's peer-reviewed
Approval Marks Biomerica’s Strategic Entry into Southeast Asia’s Rapidly Growing Healthcare MarketSimple, FDA-Cleared At-Home Test Detects an Early Warning Sign of Colorectal Cancer in Minutes IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, announced that Vietnam’s Hanoi Department of Health has officially approved the EZ Detect™ colorectal disease at-home screening test for sales and distribution throughout Vi
Operating Expenses Decline 4% Year-to-DateBalance Sheet Strengthens and Working Capital Improves by 14.7% IRVINE, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the second quarter of fiscal 2026 ended November 30, 2025. Key Highlights: 1.Biomerica Expands Commercialization of inFoods® IBS Through Collaboration with Henry Schein During the secon
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2023-04-14 | 0.16 | -0.96 | -700.00% |
| 2022-01-12 | -0.64 | -0.72 | -12.50% |
| 2021-10-14 | -0.96 | -0.96 | — |
| 2021-08-27 | -0.61 | -0.96 | -56.52% |
| 2021-04-14 | -0.48 | -1.20 | -150.00% |
| 2021-01-14 | -0.78 | -1.04 | -33.33% |
| 2020-10-15 | -0.64 | -1.12 | -75.00% |
| 2020-08-31 | -0.53 | -0.32 | +40.00% |
| 2020-04-14 | -0.52 | -0.72 | -38.46% |
| 2020-01-14 | -0.64 | -0.40 | +37.50% |
| 2019-10-15 | -0.48 | -0.40 | +16.67% |
| 2019-08-29 | -0.60 | -0.64 | -6.67% |
| 2019-04-15 | -0.40 | -0.56 | -40.00% |
| 2019-01-14 | -0.48 | -0.40 | +16.67% |
| 2018-10-15 | -0.48 | -0.40 | +16.67% |
| 2018-08-29 | -0.48 | -0.64 | -33.33% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BMRA | +9.13% | +17.73% | -5.16% | -21.64% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +6.16% | +22.37% | -1.72% | -34.33% |